VEGFA, vascular endothelial growth factor A, 7422

N. diseases: 1899; N. variants: 59
Disease: Carcinoma breast stage IV ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Bevacizumab, the first anti-VEGF agent approved in the treatment of cancer, has demonstrated efficacy in breast cancer in combination with paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer. 30939479 2019
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Bevacizumab (Avastin®) was the first anti-vascular endothelial growth factor (VEGF) targeting monoclonal antibody developed with this purpose and soon received its accelerated US Food and Drug Administration (FDA) approval for treatment of patients with metastatic breast cancer in 2008. 30515806 2019
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. 30003393 2018
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 AlteredExpression disease BEFREE However, our exploratory analysis suggests that in patients with metastatic breast cancer, the decrease of sEMP levels after chemotherapy is associated with better overall and disease free survival and might be superior to VEGFA levels as an angiogenesis-related prognostic marker. 29340882 2018
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE We show that combined ANGPT2 and VEGFA blockade by a bispecific antibody (A2V) provided superior therapeutic benefits, as compared to the single agents, in both genetically engineered and transplant tumor models, including metastatic breast cancer (MMTV-PyMT), pancreatic neuroendocrine tumor (RIP1-Tag2), and melanoma. 28404865 2017
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 GeneticVariation disease BEFREE Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer. 27195611 2016
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 AlteredExpression disease BEFREE Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer. 24703319 2014
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 GeneticVariation disease BEFREE Our results support the association of specific VEGF genotypes with clinical outcome in patients with metastatic breast cancer treated with a potentially anti-angiogenic regimen, such as weekly docetaxel. 24061601 2014
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Plasma VEGF-A is being evaluated prospectively in mBC in the MERiDiAN trial. 23422754 2013
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. 23340303 2013
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 GeneticVariation disease BEFREE Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. 21204912 2011
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 GeneticVariation disease BEFREE Recent data reported an association between VEGF-A genotype of tumors and median overall survival as well as grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer. 19663667 2009
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE The expression of cytokeratins (CK), VEGF, vascular endothelial growth factor receptor-2 (VEGF2), HIF-1alpha and phosphorylated-focal adhesion kinase (pFAK) in CTCs from 34 patients with metastatic breast cancer who had detectable CK-19 mRNA-positive CTCs was assessed using double staining experiments and confocal laser scanning microscopy. 19919679 2009
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 GeneticVariation disease BEFREE Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer. 18824714 2008
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE A vascular endothelial growth factor (VEGF) inhibitor might enhance metronomic chemotherapy in previously treated metastatic breast cancer (MBC) patients. 19028628 2008
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Serum and plasma concentrations of VEGF and serum concentration of IL-6 were measured in 87 patients with a fully documented history of metastatic breast cancer using an enzyme-linked immunoassay. 12771987 2003